{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:59:53Z","timestamp":1790503193923,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"vor","delay-in-days":109,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1053\/j.seminoncol.2017.08.004","type":"journal-article","created":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T00:02:20Z","timestamp":1505520140000},"page":"187-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Guidance Statement On  BRCA1\/2  Tumor Testing in Ovarian Cancer Patients"],"prefix":"10.1053","volume":"44","author":[{"given":"Ettore","family":"Capoluongo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"L\u00f3pez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn J.L.","family":"Ligtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgid","family":"Markiefka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi J.","family":"van Asperen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Endris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kamel-Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Percival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"R\u00f6thlisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richie","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Gonzalez","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2017.08.004_bib1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"New E J Med"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib4","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib5","first-page":"13","article-title":"The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers","volume":"19","author":"Paul","year":"2014","journal-title":"Front Bioscie (Landmark Ed)"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4065\/mcp.2010.0414","article-title":"Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer","volume":"85","author":"Pruthi","year":"2010","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/bcr1670","article-title":"International initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)","volume":"9","author":"Chenevix-Trench","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","article-title":"Cancer risks among BRCA1 and BRCA2 mutation carriers","volume":"96","author":"Levy-Lahad","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib9","article-title":"Clinical considerations of BRCA-1 and BRCA-2 mutation carrier: A review","volume":"2011","author":"Bougie","year":"2011","journal-title":"Int J Surg Oncol"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib10","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1186\/1471-2350-12-134","article-title":"A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer","volume":"12","author":"Garcia-Casado","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib11","author":"NCCN","year":"2017","journal-title":"Genetic\/familial high-risk assessment: Breast and Ovarian. Version 1"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib12","first-page":"9","article-title":"Olparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib13","series-title":"Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the Phase III SOLO2 Study","author":"Pujade-Lauraine","year":"2017"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12967-016-1027-1","article-title":"Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment","volume":"14","author":"Papa","year":"2016","journal-title":"Journal of translational medicine"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib16","doi-asserted-by":"crossref","first-page":"9575","DOI":"10.1021\/acs.jmedchem.6b00055","article-title":"An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy","volume":"59","author":"Wang","year":"2016","journal-title":"Journal of medicinal chemistry"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5301\/tj.5000558","article-title":"The current status of PARP inhibitors in ovarian cancer","volume":"102","author":"McLachlan","year":"2016","journal-title":"Tumori"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1634\/theoncologist.2015-0438","article-title":"Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer","volume":"21","author":"Parkes","year":"2016","journal-title":"The oncologist"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2009.04.002","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib22","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2011.10.009","article-title":"The epidemiology of endometrial and ovarian cancer","volume":"26","author":"Cramer","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nature reviews Cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib26","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib27","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/GIM.0b013e318032e4ab","article-title":"Prediction of BRCA1\/2 mutation status in patients with ovarian cancer from a hospital-based cohort","volume":"9","author":"Jacobi","year":"2007","journal-title":"Genetics in medicine: official journal of the American College of Medical Genetics"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejca.2003.09.016","article-title":"One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden","volume":"40","author":"Malander","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib30","first-page":"733","article-title":"The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches","volume":"10","author":"Risch","year":"2001","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib31","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/1078-0432.CCR-07-4806","article-title":"BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark","volume":"14","author":"Soegaard","year":"2008","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib32","doi-asserted-by":"crossref","first-page":"e58182","DOI":"10.1371\/journal.pone.0058182","article-title":"Prevalence of BRCA1 mutations in familial and sporadic Greek ovarian cancer cases","volume":"8","author":"Stavropoulou","year":"2013","journal-title":"PloS one"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2002.20.2.463","article-title":"Effect of BRCA mutations on the length of survival in epithelial ovarian tumors","volume":"20","author":"Ben David","year":"2002","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib35","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib36","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol: official journal of the American Society of Clinical Oncology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib38","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cncr.21276","article-title":"Prognostic impact of BRCA1 pathogenic and BRCA1\/BRCA2 unclassified variant mutations in patients with ovarian carcinoma","volume":"104","author":"Majdak","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib40","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib41","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib43","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1038\/ncomms4156","article-title":"Integrated analysis of germline and somatic variants in ovarian cancer","volume":"5","author":"Kanchi","year":"2014","journal-title":"Nature communications"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib44","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1038\/srep04026","article-title":"Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status","volume":"4","author":"Cunningham","year":"2014","journal-title":"Scientific reports"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cancergen.2011.12.005","article-title":"High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations","volume":"205","author":"Rzepecka","year":"2012","journal-title":"Cancer genetics"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib46","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib47","article-title":"Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas","author":"Weren","year":"2016","journal-title":"Human mutation"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nature reviews Cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib49","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib50","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib52","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","article-title":"Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","volume":"69","author":"Sakai","year":"2009","journal-title":"Cancer research"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib54","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer research"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1349-7006.2010.01840.x","article-title":"Secondary mutations of BRCA1\/2 and drug resistance","volume":"102","author":"Dhillon","year":"2011","journal-title":"Cancer science"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib56","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexcr.2014.01.008","article-title":"Library preparation methods for next-generation sequencing: tone down the bias","volume":"322","author":"van Dijk","year":"2014","journal-title":"Experimental cell research"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib58","author":"Larsson","year":"2008","journal-title":"European Molecular Genetics Quality Network (EMQN) best practice guidelines for molecular genetics analysis in hereditary breast\/ovarian cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib59","doi-asserted-by":"crossref","first-page":"D992","DOI":"10.1093\/nar\/gkr1160","article-title":"Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1\/BRCA2 databases","volume":"40","author":"Caputo","year":"2012","journal-title":"Nucleic acids research"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cancergencyto.2010.07.122","article-title":"A missense variant within BRCA1 exon 23 causing exon skipping","volume":"202","author":"Rouleau","year":"2010","journal-title":"Cancer genetics and cytogenetics"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib61","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cell.2014.01.051","article-title":"Synonymous mutations frequently act as driver mutations in human cancers","volume":"156","author":"Supek","year":"2014","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib62","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/ng.3414","article-title":"Intron retention is a widespread mechanism of tumor-suppressor inactivation","volume":"47","author":"Jung","year":"2015","journal-title":"Nature genetics"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib63","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/cncr.11345","article-title":"Pathology and classification of ovarian tumors","volume":"97","author":"Chen","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib64","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.cell.2012.04.023","article-title":"The life history of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib65","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1593\/neo.08584","article-title":"Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer","volume":"10","author":"Bayani","year":"2008","journal-title":"Neoplasia"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib66","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.22825","article-title":"Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing","volume":"36","author":"Samorodnitsky","year":"2015","journal-title":"Human mutation"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12907-015-0004-6","article-title":"A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing","volume":"15","author":"Ellison","year":"2015","journal-title":"BMC clinical pathology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib68","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00428-016-1919-8","article-title":"NGS-based BRCA1\/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial","volume":"468","author":"Endris","year":"2016","journal-title":"Virchows Archiv: European Journal of Pathology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nature biotechnology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib70","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsdottir","year":"2013","journal-title":"Briefings in bioinformatics"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1756-9966-29-132","article-title":"A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples","volume":"29","author":"Ellison","year":"2010","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib72","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jmoldx.2016.06.010","article-title":"Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags","volume":"18","author":"Eijkelenboom","year":"2016","journal-title":"The Journal of molecular diagnostics"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib73","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1530\/ERC-16-0116","article-title":"Evaluation of the methods to identify patients who may benefit from PARP inhibitor use","volume":"23","author":"Lim","year":"2016","journal-title":"Endocrine-related cancer"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib74","unstructured":"SGO. SGO clinical practice statement: Genetic testing for ovarian cancer 2014. Available at: https:\/\/www.sgo.org\/clinical-practice\/guidelines\/genetic-testing-for-ovarian-cancer\/. (Accessed September 2016)."},{"key":"10.1053\/j.seminoncol.2017.08.004_bib75","doi-asserted-by":"crossref","first-page":"A361","DOI":"10.1016\/j.jval.2015.09.697","article-title":"Cost-Effectiveness Analysis of Testing for Brca1 and Brca2 Mutations In Women Diagnosed With Ovarian Cancer and Their Female First- And Second Degree Relatives Using A Discrete Event Simulation: A Uk Health Service Perspective","volume":"18","author":"Eccleston","year":"2015","journal-title":"Value in Health"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib76","article-title":"[Raccomandazioni per l\u2019implementazione del test BRCA nei percorsi assistenziali e terapeutici delle pazienti con carcinoma ovarico]","author":"Bella","year":"2015","journal-title":"A cura del Gruppo di Lavoro AIOM - SIGU - SIBIOC - SIAPEC-IAP"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib77","first-page":"65","article-title":"Therapy-orienting testing of BRCA1 and BRCA2 germline mutations in women with ovarian cancer","volume":"9","author":"Claes","year":"2015","journal-title":"B J Med Oncol"},{"key":"#cr-split#-10.1053\/j.seminoncol.2017.08.004_bib78.1","unstructured":"Manual De Cancro Do Ov??rio. Available at: http:\/\/media.wix.com\/ugd\/78f4e8_52d37d414f8b4471a6f53928e0fc9ec9.pdf;"},{"key":"#cr-split#-10.1053\/j.seminoncol.2017.08.004_bib78.2","unstructured":"DSDC-oMdcdoaa. 2015. (Accessed September 2016)."},{"key":"10.1053\/j.seminoncol.2017.08.004_bib79","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s12094-015-1435-3","article-title":"SEOM clinical guidelines in Hereditary Breast and ovarian cancer","volume":"17","author":"Llort","year":"2015","journal-title":"Clinical and Translational Oncology"},{"key":"#cr-split#-10.1053\/j.seminoncol.2017.08.004_bib80.1","unstructured":"http:\/\/www.more-conference.com\/media\/pdf\/Bulgarian_Ovarial_Cancer_Guidelines_MOPE_2014.pdf;"},{"key":"#cr-split#-10.1053\/j.seminoncol.2017.08.004_bib80.2","unstructured":"M. Bulgarian ovarian cancer guidelines MOPE 2014. Available at: http:\/\/www.more-conference.com\/media\/pdf\/Bulgarian_Ovarial_Cancer_Guidelines_MOPE_2014.pdf. (Accessed September 2016)."},{"key":"10.1053\/j.seminoncol.2017.08.004_bib81","unstructured":"Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations. Available at: https:\/\/www.engage.england.nhs.uk\/consultation\/specialised-services-consultation\/user_uploads\/brca-policy.pdf NECcpgtfBaBmAa. Clinical commissioning policy: genetic testing for BRCA1 and BRCA2 mutations. 2015. (Accessed September 2016)."},{"key":"10.1053\/j.seminoncol.2017.08.004_bib82","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2217\/fon-2016-0189","article-title":"Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients","volume":"12","author":"Pinto","year":"2016","journal-title":"Future Oncology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib83","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00508-012-0173-6","article-title":"[Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families]","volume":"124","author":"Singer","year":"2012","journal-title":"Wiener klinische Wochenschrift"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib84","series-title":"Management of epithelial ovarian cancer","year":"2013"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib85","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molonc.2009.02.001","article-title":"The contribution of BRCA1 and BRCA2 to ovarian cancer","volume":"3","author":"Ramus","year":"2009","journal-title":"Molecular oncology"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib86","doi-asserted-by":"crossref","first-page":"29506","DOI":"10.1038\/srep29506","article-title":"Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","volume":"6","author":"George","year":"2016","journal-title":"Scientific reports"},{"key":"10.1053\/j.seminoncol.2017.08.004_bib87","doi-asserted-by":"crossref","first-page":"690","DOI":"10.12968\/bjon.2016.25.12.690","article-title":"The integration of BRCA testing into oncology clinics","volume":"25","author":"Percival","year":"2016","journal-title":"British Journal of Nursing"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2017.08.004_bib88","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/ejhg.2016.92","article-title":"BRCA to the future: towards best testing practice in the era of personalised healthcare","volume":"24","author":"Capoluongo","year":"2016","journal-title":"European Journal of Human Genetics"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775417300520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T15:07:08Z","timestamp":1530284828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775417300520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0093775417300520"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.08.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidance Statement On BRCA1\/2 Tumor Testing in Ovarian Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2017.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}